Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.

Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, Wilding I, Nauck M, Horowitz M

Regulatory peptides16 Jul 2008Cited by 206 (Europe PMC)

PMID18675854DOI10.1016/j.regpep.2008.07.003PepBankPUB-18675854

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialMechanism
In subjects with type 2 diabetes, exenatide at the lower dose prolonged solid gastric emptying half-time versus placebo.
In plain wordsIn people with diabetes, lower-dose exenatide slowed solid stomach emptying compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSolid gastric emptying T50, lower dose
Study
n = 17
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
5 microg BID · subcutaneous · 5 daysAs given in this study (human).
Measurements
Solid T50
111 min
5 microg exenatide
Solid T50
60 min
placebo
Source sentences
Summary
Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01);
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen subjects with type 2 diabetes participated in a randomized, single-blind, 3-period, crossover study. In each 5-day period, 5 or 10 microg exenatide or placebo was administered subcutaneously BID. Oral antidiabetic treatments were continued.
Report a problemFND-1867585401
02HumanRandomized controlled trialMechanism
In subjects with type 2 diabetes, exenatide at the higher dose prolonged solid gastric emptying half-time versus placebo.
In plain wordsIn people with diabetes, higher-dose exenatide slowed solid stomach emptying compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSolid gastric emptying T50, higher dose
Study
n = 17
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
10 microg BID · subcutaneous · 5 daysAs given in this study (human).
Measurements
Solid T50
169 min
10 microg exenatide
Solid T50
60 min
placebo
Source sentences
Summary
Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01);
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen subjects with type 2 diabetes participated in a randomized, single-blind, 3-period, crossover study. In each 5-day period, 5 or 10 microg exenatide or placebo was administered subcutaneously BID. Oral antidiabetic treatments were continued.
Report a problemFND-1867585402
03HumanRandomized controlled trialMechanism
In subjects with type 2 diabetes, exenatide at the lower dose prolonged liquid gastric emptying half-time versus placebo.
In plain wordsIn people with diabetes, lower-dose exenatide slowed liquid stomach emptying compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseLiquid gastric emptying T50, lower dose
Study
n = 17
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
5 microg BID · subcutaneous · 5 daysAs given in this study (human).
Measurements
Liquid T50
87 min
5 microg exenatide
Liquid T50
34 min
placebo
Source sentences
Summary
liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)].
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen subjects with type 2 diabetes participated in a randomized, single-blind, 3-period, crossover study. In each 5-day period, 5 or 10 microg exenatide or placebo was administered subcutaneously BID. Oral antidiabetic treatments were continued.
Report a problemFND-1867585403
04HumanRandomized controlled trialMechanism
In subjects with type 2 diabetes, exenatide at the higher dose prolonged liquid gastric emptying half-time versus placebo.
In plain wordsIn people with diabetes, higher-dose exenatide slowed liquid stomach emptying compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseLiquid gastric emptying T50, higher dose
Study
n = 17
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
10 microg BID · subcutaneous · 5 daysAs given in this study (human).
Measurements
Liquid T50
114 min
10 microg exenatide
Liquid T50
34 min
placebo
Source sentences
Summary
liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)].
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen subjects with type 2 diabetes participated in a randomized, single-blind, 3-period, crossover study. In each 5-day period, 5 or 10 microg exenatide or placebo was administered subcutaneously BID. Oral antidiabetic treatments were continued.
Report a problemFND-1867585404
05HumanRandomized controlled trialMechanism
In subjects with type 2 diabetes, exenatide reduced postprandial glucose AUC by 69-76% compared with placebo.
In plain wordsIn people with diabetes, exenatide reduced post-meal glucose exposure compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostprandial glucose AUC
Study
n = 17
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 or 10 microg BID · subcutaneous · 5 daysAs given in this study (human).
Measurements
Postprandial glucose AUC reduction
69 to 76%
exenatide versus placebo
Source sentences
Summary
Exenatide reduced postprandial glucose (area under the curve [AUC((0-6 h))]) by 69-76% and peak insulin (C(max)) by 84-86% compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen subjects with type 2 diabetes participated in a randomized, single-blind, 3-period, crossover study. In each 5-day period, 5 or 10 microg exenatide or placebo was administered subcutaneously BID. Oral antidiabetic treatments were continued.
Report a problemFND-1867585406
06HumanRandomized controlled trialMechanism
In subjects with type 2 diabetes, exenatide reduced peak insulin by 84-86% compared with placebo.
In plain wordsIn people with diabetes, exenatide reduced peak insulin compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePeak insulin concentration
Study
n = 17
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 or 10 microg BID · subcutaneous · 5 daysAs given in this study (human).
Measurements
Peak insulin reduction
84 to 86%
exenatide versus placebo
Source sentences
Summary
Exenatide reduced postprandial glucose (area under the curve [AUC((0-6 h))]) by 69-76% and peak insulin (C(max)) by 84-86% compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen subjects with type 2 diabetes participated in a randomized, single-blind, 3-period, crossover study. In each 5-day period, 5 or 10 microg exenatide or placebo was administered subcutaneously BID. Oral antidiabetic treatments were continued.
Report a problemFND-1867585407

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

07HumanNot a test of Exenatide (exendin-4) aloneObservational studyMechanism
In subjects with type 2 diabetes, gastric emptying did not differ between those with and without cardiac autonomic neuropathy.
In plain wordsIn people with diabetes, stomach emptying did not differ between those with and without cardiac autonomic neuropathy.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeGastric emptying by autonomic neuropathy
Study
n = 17
Comparator
Subjects without cardiac autonomic neuropathy
Outcome group
Gastrointestinal motility · Gastrointestinal
Source sentences
Summary
GE was not different between subjects with cardiac autonomic neuropathy (n=7), compared with those without (n=10) (P>/=0.68).
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen subjects with type 2 diabetes participated in a randomized, single-blind, 3-period, crossover study. In each 5-day period, 5 or 10 microg exenatide or placebo was administered subcutaneously BID. Oral antidiabetic treatments were continued.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1867585405
08HumanNot a test of Exenatide (exendin-4) aloneObservational studyMechanism
In subjects with type 2 diabetes, postprandial glucose rise was inversely related to solid gastric emptying half-time.
In plain wordsIn people with diabetes, slower solid stomach emptying was linked to a smaller post-meal glucose rise.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlucose rise association with gastric emptying
Study
n = 17
Outcome group
Glycemic control · Metabolic and weight
Measurements
Correlation coefficient
−0.49 r
glucose AUC and solid T50
Source sentences
Summary
There was an inverse relationship between the postprandial rise in glucose (AUC((0-3 h))) and GE (solid T(50), r=-0.49, P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Seventeen subjects with type 2 diabetes participated in a randomized, single-blind, 3-period, crossover study. In each 5-day period, 5 or 10 microg exenatide or placebo was administered subcutaneously BID. Oral antidiabetic treatments were continued.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1867585408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.